{
    "clinical_study": {
        "@rank": "6528", 
        "arm_group": [
            {
                "arm_group_label": "pracinostat plus azacitadine", 
                "arm_group_type": "Experimental", 
                "description": "60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.\n75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
            }, 
            {
                "arm_group_label": "Placebo with Azacitadine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.\n75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this randomized, double-blind, placebo-controlled study is to determine the\n      safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and\n      FDA approved treatment for Myelodysplastic Syndrome (MDS)."
        }, 
        "brief_title": "Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntary written informed consent\n\n          -  Histologically or cytologically documented diagnosis of MDS (any\n             French-American-British [FAB] classification subtype; that is classified as\n             intermediate 2 (1.5 to 2.0 points) or high risk (\u22652.5 points) according to the\n             International Prognostic Scoring System risk category, with >5% and <30% blasts, and\n             a peripheral blast count of <20,000\n\n          -  Bone marrow aspirate smears and bone marrow biopsies within 28 days of first study\n             treatment\n\n          -  There must be a clinical indication for treatment with azacitidine.\n\n          -  Previously untreated with hypomethylating agents (prior therapy with transfusions,\n             hematopoietic growth factors, or immunosuppressive therapy is allowed)\n\n          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2\n\n          -  Adequate organ function as evidenced by:\n\n               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 x the\n                  upper limit of normal (ULN) (\u22645 x ULN for patients with hepatic metastases\n\n               2. Total bilirubin \u22641.5 x ULN or total bilirubin of 2, whichever is higher\n\n               3. Serum creatinine <2 mg/dL, or creatinine clearance \u22641.5 x ULN\n\n               4. QTcF interval \u2264470 msec\n\n          -  Female or male patients \u226518 years-of-age\n\n          -  Male patients who are surgically sterile or willing to use adequate contraceptive\n             measures or abstain from heterosexual intercourse during the entire study treatment\n             period\n\n          -  Female patients who are surgically sterile or post menopausal or female patients who\n             are not of child-bearing potential and female patients of child-bearing potential who\n             agree to use adequate contraceptive measures or abstain from intercourse during the\n             study treatment period, who are not breastfeeding, and who have had a negative serum\n             pregnancy test \u22647 days prior to first study treatment.\n\n          -  Willingness and ability to comply with the trial and follow-up procedures\n\n        Exclusion Criteria:\n\n          -  Received any of the following within the specified time frame prior to administration\n             of study medication:\n\n               1. Any investigational agent within 14 days or 5 half-lives prior to first study\n                  treatment, whichever is longer\n\n               2. Previous therapy for malignancy within 21 days prior to first study treatment,\n                  including any chemotherapy, immunotherapy, biological or hormonal therapy (6\n                  weeks for nitrosoureas or mitomycin C)\n\n               3. Hydroxyurea within 48 hours prior to first study treatment\n\n               4. Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating\n                  factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or\n                  thrombopoietin receptor agonists at least 7 days (14 days for Aranesp) prior to\n                  study enrollment\n\n               5. Major surgery within 4 weeks prior to first study treatment\n\n          -  Patients that have not recovered from side effects of previous therapy\n\n          -  Cardiopulmonary function exclusion:\n\n               1. Current unstable arrhythmia requiring treatment\n\n               2. History of symptomatic congestive heart failure (New York Heart Association\n                  Classes III or IV)\n\n               3. History of myocardial infarction within 6 months of enrollment\n\n               4. Current unstable angina\n\n          -  Concomitant treatment with histone deacetylase (HDAC) inhibitors or drugs with\n             significant action as HDAC inhibitors, such as valproic acid, is not permitted\n\n          -  Clinical evidence of central nervous system involvement\n\n          -  Patients with gastrointestinal (GI) tract disease, causing the inability to take oral\n             medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical\n             procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's\n             disease, ulcerative colitis).\n\n          -  Active infection with HIV or chronic hepatitis B or C\n\n          -  Life-threatening illness unrelated to cancer, or any serious medical or psychiatric\n             illness that could, in the investigator's opinion, potentially interfere with\n             participation in this study\n\n          -  Presence of a malignant disease within the last 12 months, with the exception of\n             adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or\n             non-melanomatous skin cancer\n\n          -  Inability (including psychological, familial, sociological, or geographical\n             conditions) to comply with trial and/or follow-up procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873703", 
            "org_study_id": "MEI-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "pracinostat plus azacitadine", 
                "description": "Histone deacetylase inhibitor (HDACi)", 
                "intervention_name": "pracinostat", 
                "intervention_type": "Drug", 
                "other_name": "SB939"
            }, 
            {
                "arm_group_label": "Placebo with Azacitadine", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "pracinostat plus azacitadine", 
                    "Placebo with Azacitadine"
                ], 
                "description": "Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable", 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug", 
                "other_name": "Vidaza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Histone Deacetylase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MDS", 
            "High risk myelodysplastic syndrome", 
            "Intermediate-2 Myelodysplastic syndrome", 
            "Untreated"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "Sponsor website", 
            "url": "http://MEIPharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "christie.carter@southerncancercenter.com", 
                    "last_name": "Christie Carter", 
                    "phone": "251-607-5283"
                }, 
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36608"
                    }, 
                    "name": "Southern Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Brian Heller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lucisano.jennifer@scrippshealth.org", 
                    "last_name": "Jennifer Lucisano", 
                    "phone": "858-554-9374"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Scripps Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Marin Xavier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "juli.murphy@healthonecares.com", 
                    "last_name": "Juli Murphy, RN", 
                    "phone": "720-754-4890"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Colorado Blood Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Michael Maris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cokeefe@flcancer.com", 
                    "last_name": "Cara O'Keefe", 
                    "phone": "293-274-9930"
                }, 
                "facility": {
                    "address": {
                        "city": "Ft. Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists South"
                }, 
                "investigator": {
                    "last_name": "James Reeves, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lbellamy@woodlandsmed.com", 
                    "last_name": "Leslie Bellamy, RN", 
                    "phone": "850-696-4423"
                }, 
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32503"
                    }, 
                    "name": "Woodlands Medical Specialists"
                }, 
                "investigator": {
                    "last_name": "Rami Owera, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbiermeier@flcancer.com", 
                    "last_name": "Christine Biermeier", 
                    "phone": "727-216-1143", 
                    "phone_ext": "3081"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists North"
                }, 
                "investigator": {
                    "last_name": "David Wright, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pwright@flcancer.com", 
                    "last_name": "Patty Wright", 
                    "phone": "850-877-8166"
                }, 
                "facility": {
                    "address": {
                        "city": "Tallahassee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32308"
                    }, 
                    "name": "Florida Cancer Specialist and Research Institute"
                }, 
                "investigator": {
                    "last_name": "Scott Tetreault, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lisa.nardelli@moffitt.org", 
                    "last_name": "Lisa Nardelli", 
                    "phone": "813-745-4731"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Rami Komrokji, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jboese@fwmoh.com", 
                    "last_name": "Jenni Boese", 
                    "phone": "260-969-7818"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46804"
                    }, 
                    "name": "Fort Wayne Medical Oncology and Hematology"
                }, 
                "investigator": {
                    "last_name": "Sunil Babu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fryeba@IUPUI.edu", 
                    "last_name": "Bobbie Frye", 
                    "phone": "317-274-2992"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Simon Cancer Ctr"
                }, 
                "investigator": {
                    "last_name": "Hamid Sayar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jbriel1@jhmi.edu", 
                    "last_name": "Janet Briel", 
                    "phone": "410-955-8781"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer at Johns Hopkins"
                }, 
                "investigator": {
                    "last_name": "Amy E. Dezern, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nbongiorno@ccbdmd.com", 
                    "last_name": "Natalie Bongiorno", 
                    "phone": "240-482-0526"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "investigator": {
                    "last_name": "Ralph Boccia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tpearce1@hfhs.org", 
                    "last_name": "Tiffany Pearce", 
                    "phone": "313-916-1784"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hospital"
                }, 
                "investigator": {
                    "last_name": "Philip Kuriakose, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.luellen@hc.msu.edu", 
                    "last_name": "Karen Luellen, RN", 
                    "phone": "517-975-9534"
                }, 
                "facility": {
                    "address": {
                        "city": "Lansing", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48910"
                    }, 
                    "name": "Michigan State University"
                }, 
                "investigator": {
                    "last_name": "Anas Al-Janadi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marlene.watson@nmhs.org", 
                    "last_name": "Marlene Watson, RN", 
                    "phone": "402-354-5279"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68114"
                    }, 
                    "name": "Nebraska Methodist"
                }, 
                "investigator": {
                    "last_name": "Stefano Tarantolo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Priscilla.Sandoval@usoncology.com", 
                    "last_name": "Priscilla Sandoval", 
                    "phone": "702-952-3400", 
                    "phone_ext": "18685"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }, 
                    "name": "Comprehensive Cancer Centers of Nevada"
                }, 
                "investigator": {
                    "last_name": "Karen Jacks, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "raa2017@med.cornell.edu", 
                    "last_name": "Ramsey Abdallah", 
                    "phone": "646-962-9334"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weill Cornell Medical Center"
                }, 
                "investigator": {
                    "last_name": "Gail Roboz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ngiven@ohcare.com", 
                    "last_name": "Nicole Given, RN", 
                    "phone": "513-751-2273", 
                    "phone_ext": "27110"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care"
                }, 
                "investigator": {
                    "last_name": "James Essell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zimmerc@ccf.org", 
                    "last_name": "Cassie Zimmerman", 
                    "phone": "216-636-5646"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "investigator": {
                    "last_name": "Mikkael Sekeres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ktucker@tnonc.com", 
                    "last_name": "Kim Tucker", 
                    "phone": "423-698-1844"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology - Chattanooga"
                }, 
                "investigator": {
                    "last_name": "Bertrand M Anz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "debra.meyer@scresearch.net", 
                    "last_name": "Debra Meyer, RN", 
                    "phone": "615-524-4029"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Cancer Center, Tennessee Oncology"
                }, 
                "investigator": {
                    "last_name": "Jesus Berdeja, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbibins@mdanderson.org", 
                    "last_name": "Carol Bivins, RN", 
                    "phone": "713-792-4460"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Guillermo Garcia-Manero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.leissner@usoncology.com", 
                    "last_name": "Donna Leissner", 
                    "phone": "210-595-5626"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Care Centers of South Texas"
                }, 
                "investigator": {
                    "last_name": "Roger Lyons, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Desiree.Iriarte@swedish.org", 
                    "last_name": "Desiree Iriarte", 
                    "phone": "206-972-6200"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Swedish Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Michael Milder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS)", 
        "overall_official": [
            {
                "affiliation": "SCRI Development Innovations, LLC", 
                "last_name": "Michael R Savona, MD, FACP", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "M.D. Anderson Cancer Center", 
                "last_name": "Guillermo Garcia-Manero, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimate the relative efficacy, measured by complete remission rate of treatment wiht pracinostat plus azacitidine versus placebo plus azacitidine", 
            "measure": "Estimate efficacy", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873703"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimate the overall response rate [ORR = CR + complete remission + partial response (PR)]", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the overall hematologic improvement (HI) response rate by review of hematologic lab values each cycle including bone marrow blast counts, platelets and erythrocytes.", 
                "measure": "Hematologic Improvement", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the duration of response", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the progression-free survival (PFS) duration of pracinostat plus azacitidine and the relative benefit of that combination versus placebo plus azacitidine as assessed by the PFS hazard ratio", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Estimate the rate of leukemic transformation at landmark time points (6 months, 12 months, 18 months, and 24 months) using clinical review of hematologic lab counts each cycle", 
                "measure": "Rate of leukemic transformation", 
                "safety_issue": "No", 
                "time_frame": "6 - 24 months"
            }, 
            {
                "description": "Estimate the overall survival (OS) duration of pracinostat plus azacitidine and the relative benefit of that combination versus placebo plus azacitidine as assessed by the OS hazard ratio", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "6-24 months"
            }, 
            {
                "description": "Assess the adverse event (AE) profile of pracinostat and placebo when combined with azacitidine by clinical review of safety events by grade, relationship and event outcomes.", 
                "measure": "AE profile", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "MEI Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MEI Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}